TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02968654

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Restrictive Transfusion Strategy
Description: Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liberal Transfusion Strategy
Description: Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed.
Study: NCT04435405

Intervention type: OTHER
Intervention: Observational
Description: video footage analysis of group and individual behavioral processes.
Study: NCT01362283

Intervention type: OTHER
Intervention: Blood Sampling
Description: Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
Study: NCT01475019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Tablet, 120 mg, three times daily, for six months
Study: NCT02664779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arrhythmia diagnosis with the 6 steps method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arrhythmia diagnosis with the 4 steps method
Study: NCT02918929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP 305
Study: NCT01475019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Tablet, 120 mg, three times daily, for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: Tablet, 10 mg, once daily, for six months
Study: NCT02918929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP 305
Study: NCT01475019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and physical exercise
Description: Hypocaloric diet and regular physical exercise
Study: NCT02343978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711
Study: NCT00005797

Intervention type: DRUG
Group type: OTHER
Intervention: busulfan
Description: administered on Day -7 through Day -4. The total dose is 12.8 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
Study: NCT00479089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
Study: NCT00005797

Intervention type: DRUG
Group type: OTHER
Intervention: VP-16
Description: administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.

Intervention type: RADIATION
Group type: OTHER
Intervention: Fractionated Total Body Irradiation (FTBI)
Description: FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
Study: NCT01862185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi-quantitative procalcitonin
Study: NCT00465907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin and Irinotecan
Description: Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
Study: NCT00479089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD1839
Description: 250 mg by mouth daily, without break.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment.
Study: NCT01389479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral™
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®
Description: Intramuscular, single dose
Study: NCT03338543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS
Description: percutaneous electrical nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical nerve stimulation
Study: NCT03599856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TraceBook
Description: TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
Study: NCT02831985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general practice follow-up
Description: Post-surgery follow-up by general practitioner

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ear-nose-throat (ENT) specialist follow-up
Description: Post-surgery follow-up by ear-nose-throat (ENT) specialist
Study: NCT01585350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)
Description: Cohort 1 will be divided into three sub-groups and will receive:~* Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~* Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~* Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations
Study: NCT00479089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment.
Study: NCT03751163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Oral Product
Description: Encapsulated tranexamic acid 250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroquinone 4% Cream
Description: Hydroquinone 4% Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone 4% Cream
Description: Hydroquinone 4% Cream
Study: NCT01040403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) low
Description: olodaterol (BI 1744) low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) low
Description: olodaterol (BI 1744) low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) low
Description: olodaterol (BI 1744) low
Study: NCT03751163

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen SPF 30
Study: NCT01040403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) low
Description: olodaterol (BI 1744) low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low tiotropium bromide
Description: low tiotropium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low tiotropium bromide
Description: low tiotropium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) high
Description: olodaterol (BI 1744) high
Study: NCT03751163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen SPF 30

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo
Study: NCT00735449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%
Description: 1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol maleate 0.5%
Description: 1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005%
Description: 1 drop of latanoprost 0.005% once nightly.
Study: NCT01040403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) high
Description: olodaterol (BI 1744) high
Study: NCT00735449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005%
Description: 1 drop of latanoprost 0.005% once nightly.
Study: NCT03251560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuke Qianjin capsule
Description: Fuke Qianjin capsule 0.8g pills by mouth, three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule 0.8g pill by mouth, three times daily
Study: NCT01040403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) high
Description: olodaterol (BI 1744) high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol (BI 1744) high
Description: olodaterol (BI 1744) high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium tiotropium bromide
Description: medium tiotropium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium tiotropium bromide
Description: medium tiotropium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high tiotropium bromide
Description: high tiotropium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high tiotropium bromide
Description: high tiotropium bromide
Study: NCT04343222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: An NSAID used to treat eye pain and swelling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: An NSAID used to treat eye pain and swelling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tears
Description: eye drops to lubricate the eye and maintain moisture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tears
Description: eye drops to lubricate the eye and maintain moisture
Study: NCT01040403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04343222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: eye drops to lubricate the eye and maintain moisture
Study: NCT03664219

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isolation of IAN from implant with collagen membrane
Description: comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isolation of IAN from implant with collagen membrane
Description: comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
Study: NCT01800708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Study: NCT01040403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study: NCT01800708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone syrup
Study: NCT01040403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study: NCT01297530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY87-2243
Description: Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
Study: NCT01040403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: Respimat inhaler
Study: NCT04730921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing
Description: Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
Study: NCT00309608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin medium dose tablet once daily
Study: NCT03765073

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control
Study: NCT00309608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin high dose tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin low dose tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablets once daily
Study: NCT03424720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLE and BIS
Description: Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
Study: NCT04013490

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cassava dietary fiber capsule
Description: Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cassava dietary fiber capsule
Description: Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cassava dietary fiber capsule
Description: Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
Study: NCT06250543

Intervention type: DRUG
Group type: OTHER
Intervention: AbobotulinumtoxinA 300 UNT
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed

Intervention type: DRUG
Group type: OTHER
Intervention: AbobotulinumtoxinA 300 UNT
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed

Intervention type: DRUG
Group type: OTHER
Intervention: IncobotulinumtoxinA 100 UNT
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed

Intervention type: DRUG
Group type: OTHER
Intervention: IncobotulinumtoxinA 100 UNT
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocain
Description: 30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocain
Description: 30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: 30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: 30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution
Study: NCT03402373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycoderm
Description: soft gel contains nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soft gel without active ingredients
Study: NCT02089815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based exercise
Description: modified Otago exercise program to simple designed home based exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fall prevention education and counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fall prevention education and counseling
Study: NCT02274649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: one-to-one peer mentoring
Description: Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general peer support
Description: General (traditional) peer support includes introduction and provision of support services upon request
Study: NCT04394091

Intervention type: DEVICE
Intervention: ultrasensitive PET CT
Description: A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
Study: NCT02610218

Intervention type: OTHER
Intervention: CTC and cfDNA analysis
Description: The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.

Intervention type: OTHER
Intervention: CTC and cfDNA analysis
Description: The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study: NCT04623411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation training with classical method and serious game simulation method
Description: After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Neonatal resuscitation training with classical method
Study: NCT01099540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800 mg qd daily
Study: NCT00063817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen
Description: Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
Study: NCT02045433

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR Boost Therapy
Description: 1. Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~2. Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment.